Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis
- PMID: 17237299
- PMCID: PMC1796695
- DOI: 10.1136/bmj.39063.689375.55
Pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance: systematic review and meta-analysis
Abstract
Objective: To quantify the effectiveness of pharmacological and lifestyle interventions to prevent or delay type 2 diabetes in people with impaired glucose tolerance.
Data sources: Medline, Embase, and the Cochrane library searched up to July 2006. Expert opinions sought and reference lists of identified studies and any relevant published reviews checked.
Study selection: Randomised controlled trials that evaluated interventions to delay or prevent type 2 diabetes in individuals with impaired glucose tolerance.
Results: 21 trials met the inclusion criteria, of which 17, with 8084 participants with impaired glucose tolerance, reported results in enough detail for inclusion in the meta-analyses. From the meta-analyses the pooled hazard ratios were 0.51 (95% confidence interval 0.44 to 0.60) for lifestyle interventions v standard advice, 0.70 (0.62 to 0.79) for oral diabetes drugs v control, 0.44 (0.28 to 0.69) for orlistat v control, and 0.32 (0.03 to 3.07) for the herbal remedy jiangtang bushen recipe v standard diabetes advice. These correspond to numbers needed to treat for benefit (NNTB) and harm (NNTH) of 6.4 for lifestyle (95% credible interval, NNTB 5.0 to NNTB 8.4), 10.8 for oral diabetes drugs (NNTB 8.1 to NNTB 15.0), 5.4 for orlistat (NNTB 4.1 to NNTB 7.6), and 4.0 for jiangtang bushen (NNTH 16.9 to NNTB 24.8).
Conclusions: Lifestyle and pharmacological interventions reduce the rate of progression to type 2 diabetes in people with impaired glucose tolerance. Lifestyle interventions seem to be at least as effective as drug treatment.
Conflict of interest statement
Figures
Comment in
-
Review: lifestyle or pharmacological interventions prevent or delay type 2 diabetes in people with impaired glucose tolerance.Evid Based Nurs. 2007 Jul;10(3):78. doi: 10.1136/ebn.10.3.78. Evid Based Nurs. 2007. PMID: 17596383 No abstract available.
-
Review: lifestyle or pharmacologic interventions prevent or delay type 2 diabetes in impaired glucose tolerance.ACP J Club. 2007 Jul-Aug;147(1):1. ACP J Club. 2007. PMID: 17608366 No abstract available.
-
Review: Lifestyle or pharmacological interventions prevent or delay type 2 diabetes in impaired glucose tolerance.Evid Based Med. 2007 Aug;12(4):108. doi: 10.1136/ebm.12.4.108. Evid Based Med. 2007. PMID: 17885156 No abstract available.
Similar articles
-
Cannabis-based medicines for chronic neuropathic pain in adults.Cochrane Database Syst Rev. 2018 Mar 7;3(3):CD012182. doi: 10.1002/14651858.CD012182.pub2. Cochrane Database Syst Rev. 2018. PMID: 29513392 Free PMC article.
-
Interventions for non-oliguric hyperkalaemia in preterm neonates.Cochrane Database Syst Rev. 2007 Jan 24;(1):CD005257. doi: 10.1002/14651858.CD005257.pub2. Cochrane Database Syst Rev. 2007. Update in: Cochrane Database Syst Rev. 2012 May 16;(5):CD005257. doi: 10.1002/14651858.CD005257.pub3. PMID: 17253550 Updated.
-
Systematic review of the long-term effects and economic consequences of treatments for obesity and implications for health improvement.Health Technol Assess. 2004 May;8(21):iii-iv, 1-182. doi: 10.3310/hta8210. Health Technol Assess. 2004. PMID: 15147610
-
Antidepressants versus placebo for panic disorder in adults.Cochrane Database Syst Rev. 2018 Apr 5;4(4):CD010676. doi: 10.1002/14651858.CD010676.pub2. Cochrane Database Syst Rev. 2018. PMID: 29620793 Free PMC article.
-
Alpha-glucosidase inhibitors for people with impaired glucose tolerance or impaired fasting blood glucose.Cochrane Database Syst Rev. 2006 Oct 18;(4):CD005061. doi: 10.1002/14651858.CD005061.pub2. Cochrane Database Syst Rev. 2006. Update in: Cochrane Database Syst Rev. 2018 Dec 28;12:CD005061. doi: 10.1002/14651858.CD005061.pub3. PMID: 17054235 Updated.
Cited by
-
Benzylglucosinolate Derived Isothiocyanate from Tropaeolum majus Reduces Gluconeogenic Gene and Protein Expression in Human Cells.PLoS One. 2016 Sep 13;11(9):e0162397. doi: 10.1371/journal.pone.0162397. eCollection 2016. PLoS One. 2016. PMID: 27622707 Free PMC article.
-
Aggregation of type-2 diabetes, prediabetes, and metabolic syndrome in German couples.Sci Rep. 2024 Feb 5;14(1):2984. doi: 10.1038/s41598-024-53417-1. Sci Rep. 2024. PMID: 38316913 Free PMC article.
-
Exploring medication self-management in polypharmacy: a qualitative systematic review of patients and healthcare providers perspectives.Front Pharmacol. 2024 Sep 13;15:1426777. doi: 10.3389/fphar.2024.1426777. eCollection 2024. Front Pharmacol. 2024. PMID: 39376612 Free PMC article.
-
Behavior change in a lifestyle intervention for type 2 diabetes prevention in Dutch primary care: opportunities for intervention content.BMC Fam Pract. 2013 Jun 7;14:78. doi: 10.1186/1471-2296-14-78. BMC Fam Pract. 2013. PMID: 23758998 Free PMC article. Clinical Trial.
-
Association of circulating irisin levels with normal weight obesity, glycemic and lipid profile.J Diabetes Metab Disord. 2016 Jun 27;15:17. doi: 10.1186/s40200-016-0239-5. eCollection 2015. J Diabetes Metab Disord. 2016. PMID: 27354972 Free PMC article.
References
-
- Davies MJ, Tringham JR, Troughton J, Khunti KK. Prevention of type 2 diabetes mellitus. A review of the evidence and its application in a UK setting. Diabet Med 2004;21:403-14. - PubMed
-
- Department of Health. National service framework for diabetes: standards. London: DoH, 2001.
-
- Angelo JB, Huang J, Carden D. Diabetes prevention: a review of current literature. Adv Stud Med 2005;5:250-9.
-
- Anderson DC Jr. Pharmacologic prevention or delay of type 2 diabetes mellitus. Ann Pharmacother 2005;39:102-9. - PubMed
Publication types
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous